These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 9123184)
1. Genetic modification of an islet tumor cell line inhibits its rejection. Georgiou HM; Brady JL; Silva A; Lew AM Transplant Proc; 1997; 29(1-2):1032-3. PubMed ID: 9123184 [No Abstract] [Full Text] [Related]
2. Enhanced survival of grafts genetically endowed with the ability to block CD2 and B7. Brady JL; Yamashita K; Lew AM Cell Transplant; 2001; 10(2):175-81. PubMed ID: 11332632 [TBL] [Abstract][Full Text] [Related]
3. Secretion of CTLA4Ig by an SV40 T antigen-transformed islet cell line inhibits graft rejection against the neoantigen. Lew AM; Brady JL; Silva A; Coligan JE; Georgiou HM Transplantation; 1996 Jul; 62(1):83-9. PubMed ID: 8693551 [TBL] [Abstract][Full Text] [Related]
4. Additive efficacy of CTLA4Ig and OX40Ig secreted by genetically modified grafts. Brady JL; Lew AM Transplantation; 2000 Mar; 69(5):724-30. PubMed ID: 10755517 [TBL] [Abstract][Full Text] [Related]
5. Evidence that the adenoviral vector containing the CTLA4-Ig gene improves transgene expression and graft survival. Namii Y; Hayashi S; Yokoyama I; Kobayashi T; Yasutomi M; Nagasaka T; Uchida K; Hamada H; Takagi H Transplant Proc; 1997 May; 29(3):1738-9. PubMed ID: 9142255 [No Abstract] [Full Text] [Related]
6. Immunotherapy with nondepleting anti-CD4 monoclonal antibodies but not CD28 antagonists protects islet graft in spontaneously diabetic nod mice from autoimmune destruction and allogeneic and xenogeneic graft rejection. Guo Z; Wu T; Kirchhof N; Mital D; Williams JW; Azuma M; Sutherland DE; Hering BJ Transplantation; 2001 Jun; 71(11):1656-65. PubMed ID: 11435979 [TBL] [Abstract][Full Text] [Related]
7. Expression of functional human Epstein-Barr virus/C3d receptor ([CR2] CD21) on insulinoma cell line. Induction of tumor rejection but not diabetes in syngeneic rats. Carel JC; Holers VM; Chick WL; Littman D; Lacy PE Diabetes; 1991 Jul; 40(7):809-14. PubMed ID: 1647992 [TBL] [Abstract][Full Text] [Related]
8. Locally expressed CTLA4-Ig in a pancreatic beta-cell line suppresses accelerated graft rejection response induced by donor-specific transfusion. Kimura F; Gotoh M; Tanaka T; Luo Z; Miyazaki J; Uede T; Monden M; Miyasaka M Diabetologia; 2002 Jun; 45(6):831-40. PubMed ID: 12107727 [TBL] [Abstract][Full Text] [Related]
9. Cutting edge: targeted ligation of CTLA-4 in vivo by membrane-bound anti-CTLA-4 antibody prevents rejection of allogeneic cells. Hwang KW; Sweatt WB; Brown IE; Blank C; Gajewski TF; Bluestone JA; Alegre ML J Immunol; 2002 Jul; 169(2):633-7. PubMed ID: 12097362 [TBL] [Abstract][Full Text] [Related]
10. Effect of CTLA4-Ig gene transfer using adenoviral vector in organ and cell transplantation. Hayashi S; Namii Y; Kozima T; Kobayashi T; Yokoyama I; Saito I; Hamada H; Ohtsuka S; Uchida K; Takagi H Transplant Proc; 1997 Jun; 29(4):2212. PubMed ID: 9193596 [No Abstract] [Full Text] [Related]
11. Effects of locally expressed CTLA4-Ig in a pancreatic beta cell line on the accelerated graft rejection response induced by DST. Kimura F; Gotoh M; Tanaka T; Luo Z; Miyazaki J; Monden M; Uede T; Miyasaka M Transplant Proc; 2001; 33(1-2):552. PubMed ID: 11266954 [No Abstract] [Full Text] [Related]
12. Treatment with CTLA4-Ig inhibits rejection of liver allografts from FIt3-ligand-treated donors. Fu F; Li W; Lu L; Fung JJ; Thomson AW; Qian S Transplant Proc; 1999; 31(1-2):453. PubMed ID: 10083185 [No Abstract] [Full Text] [Related]
14. Local production of CTLA4-Ig by adenoviral-mediated gene transfer to the pancreas induces permanent allograft survival and donor-specific tolerance. Liu C; Deng S; Yang Z; Kucher T; Guo F; Gelman A; Chen H; Naji A; Shaked A; Brayman KL Transplant Proc; 1999; 31(1-2):625-6. PubMed ID: 10083267 [No Abstract] [Full Text] [Related]
15. Addition of an IL-15 mutant/FCgamma2A antagonist protein protects islet allografts from rejection overriding costimulation blockade. Ferrari-Lacraz S; Zheng XX; Kim YS; Maslinski W; Strom TB Transplant Proc; 2002 May; 34(3):745-7. PubMed ID: 12034169 [No Abstract] [Full Text] [Related]
16. Adenovirus-mediated gene transfer of CTLA4Ig to liver allografts results in prolonged survival and local T-cell anergy. Olthoff KM; Da Chen X; Gelman A; Turka L; Shaked A Transplant Proc; 1997; 29(1-2):1030-1. PubMed ID: 9123183 [No Abstract] [Full Text] [Related]
17. Systemic administration of CTLA4-Ig or anti-CD40 ligand antibody inhibits second-set rejection of mouse liver allografts. Fu F; Li W; Lu L; Thomson AW; Fung JJ; Qian S Transplant Proc; 1999; 31(1-2):1244. PubMed ID: 10083555 [No Abstract] [Full Text] [Related]
18. Tolerance to a second donor-matched allograft following local immune modulation using transfer of sequences encoding CTLA4Ig. Shaked A; Olthoff K; Sellers M; Chen XD; Gelman A Transplant Proc; 1997; 29(1-2):1026. PubMed ID: 9123180 [No Abstract] [Full Text] [Related]
19. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. van Elsas A; Hurwitz AA; Allison JP J Exp Med; 1999 Aug; 190(3):355-66. PubMed ID: 10430624 [TBL] [Abstract][Full Text] [Related]
20. Prevention of autoimmune recurrence and rejection by adenovirus-mediated CTLA4Ig gene transfer to the pancreatic graft in BB rat. Uchikoshi F; Yang ZD; Rostami S; Yokoi Y; Capocci P; Barker CF; Naji A Diabetes; 1999 Mar; 48(3):652-7. PubMed ID: 10078573 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]